These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20370645)

  • 21. P38 MAP kinase is involved in oleuropein-induced apoptosis in A549 cells by a mitochondrial apoptotic cascade.
    Cao S; Zhu X; Du L
    Biomed Pharmacother; 2017 Nov; 95():1425-1435. PubMed ID: 28946190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ENMD-2076 for hematological malignancies.
    How J; Yee K
    Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cell-death-defying factor, anamorsin mediates cell growth through inactivation of PKC and p38MAPK.
    Saito Y; Shibayama H; Tanaka H; Tanimura A; Kanakura Y
    Biochem Biophys Res Commun; 2011 Feb; 405(2):303-7. PubMed ID: 21219862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammalian target of rapamycin as a target in hematological malignancies.
    Abdel-Karim IA; Giles FJ
    Curr Probl Cancer; 2008; 32(4):161-77. PubMed ID: 18655914
    [No Abstract]   [Full Text] [Related]  

  • 27. Cancer suppression by systemic inactivation of p38MAPK.
    Brichkina A; Bulavin DV
    Oncotarget; 2017 Feb; 8(9):14275-14276. PubMed ID: 28199960
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
    Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
    Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of p38 in regulation of hematopoiesis: effect of p38 inhibition on cytokine production and transcription factor activity in human bone marrow stromal cells.
    Scicchitano MS; McFarland DC; Tierney LA; Boyce RW; Frazier KS; Schwartz LW; Thomas HC
    Blood Cells Mol Dis; 2008; 40(3):370-80. PubMed ID: 18093851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New and emerging drug targets for the treatment of hematological malignancies.
    Bendall LJ
    Curr Drug Targets; 2010 Jul; 11(7):767-8. PubMed ID: 20370651
    [No Abstract]   [Full Text] [Related]  

  • 33. p38MAP Kinase activity is required for human primary adipocyte differentiation.
    Aouadi M; Jager J; Laurent K; Gonzalez T; Cormont M; Binétruy B; Le Marchand-Brustel Y; Tanti JF; Bost F
    FEBS Lett; 2007 Dec; 581(29):5591-6. PubMed ID: 17997987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential p38 mitogen-activated protein kinase-controlled hypophosphorylation of the retinoblastoma protein induced by nitric oxide in neuroblastoma cells.
    González-Fernández O; Jiménez A; Villalobo A
    Free Radic Biol Med; 2008 Feb; 44(3):353-66. PubMed ID: 17976389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Wnt signaling pseudokinases in hematological cancers.
    Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
    Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of the p38MAPK signalling pathway to proliferation in human cultured airway smooth muscle cells is mitogen-specific.
    Fernandes DJ; Ravenhall CE; Harris T; Tran T; Vlahos R; Stewart AG
    Br J Pharmacol; 2004 Aug; 142(7):1182-90. PubMed ID: 15249425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of autophagy in hematological malignancies: role of reactive oxygen species.
    Ishdorj G; Li L; Gibson SB
    Leuk Lymphoma; 2012 Jan; 53(1):26-33. PubMed ID: 21749305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advance in the study on p38 MAPK mediated drug resistance in leukemia.
    Gao F; Liu WJ
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1064-70. PubMed ID: 27049258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer associated fibroblasts in hematological malignancies.
    Raffaghello L; Vacca A; Pistoia V; Ribatti D
    Oncotarget; 2015 Feb; 6(5):2589-603. PubMed ID: 25474039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.